mesalamine has been researched along with ur 12746 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gálvez, J; Garrido, M; Merlos, M; Torres, MI; Zarzuelo, A | 1 |
| Carceller, E; Escamilla, I; Ferrando, R; Forn, J; García-Rafanell, J; Giral, M; Merlos, M; Ramis, J; Salas, J | 1 |
| de Medina, FS; Gálvez, J; Garrido, M; Merlos, M; Ramis, I; Rodríguez-Cabezas, ME; Zarzuelo, A | 1 |
| Aceituno, M; Balsa, D; Esteller, M; Lozano, JJ; Merlos, M; Panés, J; Planell, N; Pontes, C; Román, J; Salas, A | 1 |
| Panés, J; Pontes, C; Torres, F; Vives, R | 1 |
2 trial(s) available for mesalamine and ur 12746
| Article | Year |
|---|---|
Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Differentiation; Azo Compounds; Case-Control Studies; CD18 Antigens; Cohort Studies; Colitis, Ulcerative; Double-Blind Method; Female; Gene Expression Profiling; Genetic Markers; Humans; Interleukin-2 Receptor alpha Subunit; Logistic Models; Male; Mesalamine; Middle Aged; Polymerase Chain Reaction; Receptors, Interleukin-1 Type II; Sensitivity and Specificity; Severity of Illness Index; Transcriptome; Treatment Outcome | 2013 |
Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Azo Compounds; Colitis, Ulcerative; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Mesalamine; Middle Aged; Severity of Illness Index; Treatment Outcome; Young Adult | 2014 |
3 other study(ies) available for mesalamine and ur 12746
| Article | Year |
|---|---|
Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat.
Topics: Acute Disease; Aminosalicylic Acids; Animals; Anti-Inflammatory Agents; Aza Compounds; Chronic Disease; Colitis; Colon; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gastrointestinal Agents; Intestinal Mucosa; Intestines; Male; Mesalamine; Platelet Activating Factor; Rabbits; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sulfasalazine; Trinitrobenzenesulfonic Acid | 2000 |
Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.
Topics: Amines; Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aza Compounds; Azo Compounds; Colitis, Ulcerative; Drug Evaluation, Preclinical; Female; Hypotension; Imidazoles; Male; Mesalamine; Platelet Activating Factor; Platelet Aggregation; Prodrugs; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship; Trinitrobenzenesulfonic Acid | 2001 |
The intestinal anti-inflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aza Compounds; Azo Compounds; Cell Line; Colitis; Colon; Cytokines; Down-Regulation; Female; Inflammation Mediators; Interleukin-1; Interleukin-8; Mesalamine; Neutrophil Infiltration; Peroxidase; Platelet Activating Factor; Rats; Rats, Wistar; Secondary Prevention; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2003 |